Synonyms: GSK-2141795 | GSK2141795
Compound class:
Synthetic organic
Comment: Uprosertib (GSK-2141795) is an inhibitor of the AKT family of protein kinases [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Uprosertib has progressed to Phase 2 clinical evaluation. In most studies it was administered in combination with other antineoplastics for various oncological indications, such as melanoma, refractory multiple myeloma, acute myeloid leukemia, cervical cancer, endometrial carcinoma and metastatic triple-negative breast cancer. Click here to link to ClinicalTrials.gov's complete list of uprosertib trials. |